clinical trial · NCT03773965
A Study of Baricitinib in Participants From 1 Year to Less Than 18 Years Old With Juvenile Idiopathic Arthritis
Eli Lilly and Company·phase3·recruiting·n = 190
Juvenile Idiopathic ArthritisBaricitinib
brief summary
The reason for this study is to see if the study drug baricitinib is safe and effective in the treatment of JIA in participants ages 1 to 17. This study is for participants that have been enrolled in studies I4V-MC-JAHV (NCT03773978) or I4V-MC-JAHU.
started
Apr 5, 2019
primary completion
Jul 1, 2031
completion
Jul 1, 2031
last updated
Feb 10, 2026
official title
A Phase 3 Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients From 1 Year to <18 Years of Age With Juvenile Idiopathic Arthritis (JIA)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol